Research Context: The Peptides in Our Catalogue and How They Are Studied

This article summarizes, at a high level, what the research literature describes about the peptides in the Elysium Bio Labs catalogue — what each compound is and the mechanisms and research areas it is studied in.

It is informational and describes preclinical and mechanistic research only. It is not administration, dosing, or clinical guidance, and it does not describe human use. All materials are supplied strictly for laboratory and research use — not for human or veterinary use. Several of these compounds are not approved drugs.

Retatrutide — a triple receptor agonist studied in metabolic research

Retatrutide is a synthetic peptide characterized in the literature as a triple receptor agonist, engineered to act simultaneously at the GLP-1, GIP, and glucagon (GCGR) receptors. It is a single peptide coupled to a fatty-diacid moiety that extends its half-life.

In metabolic research models, these three pathways are studied together: GLP-1 and GIP signalling in relation to glucose-stimulated insulin secretion and satiety, and glucagon-receptor activation in relation to energy expenditure. Reported receptor profiling describes it as relatively more potent at the GIP receptor than at the GLP-1 and glucagon receptors. Retatrutide is an investigational compound; it is used here as a research reference material for studying incretin and glucagon-receptor biology, and no human-use or efficacy claims are made.

GHK-Cu — a copper-binding tripeptide studied in cellular and skin research

GHK-Cu is the copper(II) complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys), bound in a 1:1 ratio. It was first isolated from human plasma in 1973, and circulating levels are reported to decline with age — an observation that motivated much of the research on the exogenous peptide.

Research characterizes GHK's copper-coordinating capacity as central to its activity, because copper is a cofactor for enzymes such as lysyl oxidase (collagen/elastin cross-linking) and superoxide dismutase (antioxidant defence). Gene-expression analyses have described GHK modulating a large number of human genes concentrated in tissue-repair, antioxidant, and anti-inflammatory pathways, and fibroblast/wound-model studies report effects on collagen and extracellular-matrix remodelling. It is studied in cellular and skin research contexts — it is not a metabolic peptide.

BPC-157 — a pentadecapeptide studied in preclinical tissue-repair models

BPC-157 ("Body Protection Compound-157") is a synthetic pentadecapeptide corresponding to a partial sequence of a protein identified in gastric juice. The research is overwhelmingly preclinical (in-vitro and animal models).

In those models, researchers have studied its association with angiogenesis and tissue-repair pathways, including reported effects on VEGF and ERK1/2 signalling, nitric-oxide pathways, collagen synthesis, and fibroblast activity, across gastrointestinal, tendon, ligament, muscle, and bone injury models. Importantly for research context: BPC-157 is not an approved drug, does not appear in pharmacopoeial monographs, and has been prohibited in sport by WADA since 2022. Human clinical evidence is very limited.

TB-500 — a Thymosin β4 fragment studied in cell-migration research

TB-500 is a synthetic peptide corresponding to the actin-binding region of Thymosin β4 (Tβ4), a naturally occurring 43-residue protein; the fragment contains the central actin-binding motif (LKKTETQ).

The established mechanism studied in the literature is G-actin sequestration: by binding actin monomers and holding them in a polymerization-incompetent state, Tβ4 (and the TB-500 fragment) is studied in relation to the actin dynamics that underlie cell migration, angiogenesis, and tissue remodelling. Reported experimental findings — largely from in-vitro assays and animal models — describe effects on the migration of endothelial cells and keratinocytes. Human clinical data are limited.

How to read this research

A few points that matter when interpreting any of the above:

• Preclinical ≠ human. Most of this work is in cell or animal models. Findings in those systems do not establish safety or effect in humans, and nothing here should be read as implying human use.
• Mechanism ≠ outcome. Describing a receptor or pathway a compound acts on is not a claim about what it does in any organism.
• Regulatory status varies. Several of these compounds are investigational or unapproved, and some are restricted in sport. Compliance with applicable laws and institutional requirements is the researcher's responsibility.
• Batch data is separate. This article is general reference information about the compounds; it is not batch-specific analytical data. For batch documentation, see our documentation policy and how to read a certificate of analysis.

References

• Retatrutide mechanism — Eli Lilly Medical; review, NCBI PMC
• GHK-Cu gene-expression research — OBM Genetics (LIDSEN)
• BPC-157 tissue-repair review — NCBI PMC; NCBI PMC commentary